Assessment of Galectin-1, Galectin-3, and Prostaglandin E2 Levels in Patients with COVID-19

1. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate COVID-19. N Engl J Med. 2020;383: 1757-66.

2. Liu X, Shi S, Xiao J, et al. Prediction of the severity of the coronavirus disease and its adverse clinical outcomes. Jpn J Infect Dis. 2020;73:404-10.

3. Bastug A, Bodur H, Erdogan S, et al. Clinical and laboratory features of COVID-19: predictors of severe prognosis. Immunopharmacol. 2020;88:106950.

4. Kazancioglu S, Bastug A, Ozbay BO, et al. The role of haematological parameters in patients with COVID-19 and influenza virus infection. Epidemiol and Infect. 2020;148:e272.

5. Kermali M, Khalsa RK, Pillai K, et al. The role of biomarkers in diagnosis of COVID-19–a systematic review. Life Sci. 2020;254:117788.

6. Li H, Xiang X, Ren H, et al. Serum amyloid A is a biomarker of severe coronavirus disease and poor prognosis. J Infect. 2020;80:646-55.

7. Zaninotto M, Mion MM, Cosma C, et al. Presepsin in risk stratification of SARS-CoV-2 patients. Clin Chim Acta. 2020;507:161-3.

8. Caniglia JL, Guda MR, Asuthkar S, et al. A potential role for galectin-3 inhibitors in the treatment of COVID-19. PeerJ. 2020;8:e9392.

9. Sethi A, Sanam S, Munagalasetty S, et al. Understanding the role of galectin inhibitors as potential candidates for SARS-CoV-2 spike protein: in silico studies. RSC Adv. 2020;10: 29873-84.

10. Machala EA, McSharry BP, Rouse BT, et al. Gal power: the diverse roles of galectins in regulating viral infections. J Gen Virol. 2019;100:333-49.

11. Wang WH, Lin CY, Chang MR, et al. The role of galectins in virus infection - a systemic literature review. J Microbiol Immunol Infect. 2020;53:925-35.

12. Stowell SR, Qian Y, Karmakar S, et al. Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion. J Immunol. 2008;180:3091-102.

13. Garcia-Revilla J, Deierborg T, Venero JL, et al. Hyperinflammation and fibrosis in severe COVID-19 patients: galectin-3, a target molecule to consider. Front Immunol. 2020;11:2069.

14. Hoxha M. What about COVID-19 and arachidonic acid pathway? Eur J Clin Pharmacol. 2020;76:1501-4.

15. Robb CT, Goepp M, Rossi AG, et al. Non‐steroidal anti‐inflammatory drugs, prostaglandins, and COVID‐19. Br J Pharmacol. 2020;177:4899-920.

16. Steer SA, Corbett JA. The role and regulation of COX-2 during viral infection. Viral Immunol. 2003;16:447-60.

17. Hong W, Chen Y, You K, et al. Celebrex adjuvant therapy on COVID-19: an experimental study. Front Pharmacol. 2020;11:561674.

18. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Available at <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>. Accessed February 15, 2021.

19. Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25-32.

20. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-c-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol. 2020;92:1733-4.

21. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71:762-8.

22. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19. Allergy. 2020;75:1564-81.

23. Baghaki S, Yalcin CE, Baghaki HS, et al. COX2 Inhibition in the treatment of COVID-19: review of literature to propose celecoxib repositioning for randomized controlled studies. Int J Infect Dis. 2020;101:29-32.

24. Cain DW, Cidlowski JA. After 62 years of regulating immunity, dexamethasone meets COVID-19. Nat Rev Immunol. 2020;20:587-8.

25. Kazancioglu S, Yilmaz FM, Bastug A, et al. Lymphocyte subset alteration and monocyte CD4 expression reduction in patients with severe COVID-19.Viral Immunol. 2021;34:342-51.

26. Pence BD. Severe COVID-19 and aging: are monocytes the key? Geroscience. 2020;42:1051-61.

27. US Nationale Library of Medicine. A study to test the efficacy and safety of inhaled TD139 in subjects with idiopathic pulmonary fibrosis (IPF). Available at <https://clinicaltrials.gov/ct2/show/NCT03832946>. Accessed February 15, 2021.

28. Ho JE, Gao W, Levy D, et al. Galectin-3 is associated with restrictive lung disease and interstitial lung abnormalities. Am J Respir Crit Care Med. 2016;194:77-83.

29. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807-15.

30. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J Infect. 2020;80:607-13.

31. Nita-Lazar M, Banerjee A, Feng C, et al. Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding. Mol Immunol. 2015;65:1-16.

32. Yang ML, Chen YH, Wang SW, et al. Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis. J Virol. 2011;85,10010-20.

33. Caniglia JL, Asuthkar S, Tsung AJ, et al. Immunopathology of galectin-3: an increasingly promising target in COVID-19. F1000Res. 2020;9:1078.

34. Nita-Lazar M, Banerjee A, Feng C, et al. Galectins regulate the inflammatory response in airway epithelial cells exposed to microbial neuraminidase by modulating the expression of SOCS1 and RIG1. Mol Immunol. 2015;68:194-202.